Roche sees another Rituxan biosimilar bite the dust FierceBiotech Samsung Electronics and Teva Pharmaceutical ($TEVA) both bailed out on biosimilar versions of rituximab (MabThera/Rituxan) last year amid uncertainty in regulation of copycat biologics in the U.S. and expensive development requirements that reduce the ... Celltrion Drops Late-Stage Trial of Roche Rituxan Drug Copy |
